Be that as it may, low expression of BHLHE40, LDLR or EMP1 and a weak STAT3 activity are associated with a good prognosis in several cancers [37, 38], and STAT3 inhibitors such as Napabucasin (BBI608) are FDA-approved in pancreatic cancer and give promising results in CRC clinical trials, alone or in combination [46, 63]. This evidence concerns the gene LDLR and colorectal carcinoma.